Works Cited

1. Institute of Medicine Committee on Sleep Medicine and Research, Colten HR, Altevogt BM (eds). Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academies Press; 2006.

2. American Academy of Sleep Medicine. The International Classification of Sleep Disorders-3: Diagnostic and Coding Manual. 3rd ed. Westchester, IL: American Academy of Sleep Medicine; 2014.

3. Skaer TL, Sclar DA. Economic implications of sleep disorders. Pharmacoeconomics. 2010;28(11):1015-1023.

4. National Commission of Sleep Disorders Research. Wake Up America: A National Sleep Alert: Report of the National Commission on Sleep Disorders Research. Washington, DC: The National Commission; 1993, 1994.

5. U.S. Department of Transportation, National Highway Traffic Safety Administration. Drowsy Driving. Available at https://www.nhtsa.gov/risky-driving/drowsy-driving. Last accessed December 3, 2018.

6. Wittmann V, Rodenstein DO. Health care costs and the sleep apnea syndrome. Sleep Med Rev. 2004;8(4):269-279.

7. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep. 1994;17(1):84-93.

8. Webb WB. The cost of sleep-related accidents: a reanalysis. Sleep. 1995;18(4):276-280.

9. Leger D. The cost of sleepiness: a response to comments. Sleep. 1995;18(4):281-284.

10. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of U.S. workers: results from the America Insomnia Survey. Sleep. 2011;34(9):1161-1171.

11. Hirsch Allen AJ, Bansback N, Ayas NT. The effect of OSA on work disability and work-related injuries. Chest. 2015;147(5): 1422-1428.

12. Ohayon MM, Schenck CH. Violent behavior during sleep: prevalence, comorbidity and consequences. Sleep Med. 2010;11(9): 941-946.

13. Grover M, Mookadam M, Armas D, et al. Identifying patients at risk for obstructive sleep apnea in a primary care practice.J Am Board Fam Med. 2011;24(2):152-160.

14. Roth T, Bogan RK, Culpepper L, et al. Excessive sleepiness: under-recognized and essential marker for sleep/wake disorder management. Curr Med Res Opin. 2010;26(Suppl 2):S3-S24.

15. Wang CL, Li XZ, Cai XL, Pan XL, Min J. Anesthesiologist's knowledge and attitudes about obstructive sleep apnea: a survey study. Sleep Breath. 2012;16(1):41-46.

16. National Sleep Foundation. Sleep-Wake Cycle: Its Physiology and Impact on Health. Available at http://www.sleepfoundation.org/sites/default/files/SleepWakeCycle.pdf. Last accessed December 3, 2018.

17. National Institute of General Medical Sciences. Circadian Rhythms. Available at https://www.nigms.nih.gov/education/pages/factsheet_circadianrhythms.aspx. Last accessed December 3, 2018.

18. Korczak AL, Martynhak BJ, Pedrazzoli M, Brito AF, Louzada FM. Influence of chronotype and social zeitgebers on sleep/wake patterns. Braz J Med Biol Res. 2008;41(10):914-919.

19. Zimmermann LK. Chronotype and the transition to college life. Chronobiol Int. 2011;28(10):904-910.

20. Vollmer C, Michel U, Randler C. Outdoor light at night (LAN) is correlated with eveningness in adolescents. Chronobiol Int. 2012;29(4):502-508.

21. Hughes AT, Piggins HD. Feedback actions of locomotor activity to the circadian clock. Prog Brain Res. 2012;199:305-336.

22. Santrock JW, Mitterer JO. Psychology. 3rd ed. Toronto: McGraw-Hill Ryerson; 2006.

23. Bodenstein C, Heiland I, Schuster S. Temperature compensation and entrainment in circadian rhythms. Phys Biol. 2012;9(3):036011.

24. Mistlberger RE, Skene DJ. Nonphotic entrainment in humans? J Biol Rhythms. 2005;20(4):339-352.

25. Huang ZL, Urade Y, Hayaishi O. The role of adenosine in the regulation of sleep. Curr Top Med Chem. 2011;11(8):1047-1057.

26. Brown GM. Light, melatonin and the sleep-wake cycle. J Psychiatry Neurosci. 1994;19(5):345-353.

27. Kaplan PW, Fisher RS (eds). Imitators of Epilepsy. 2nd ed. New York, NY: Demos Medical Publishing; 2005.

28. Williams RL, Karacan I, Hursch CJ. EEG of Human Sleep: Clinical Applications. New York, NY: John Wiley & Sons; 1974.

29. Kales A, Kales JD. Sleep disorders: recent findings in the diagnosis and treatment of disturbed sleep. N Engl J Med. 1974;290(9):487-499.

30. Chervin RD, Aldrich MS. Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea.Am J Respir Crit Care Med. 2000;161(2 Pt 1):426-431.

31. National Sleep Foundation. Sleep Hygiene. Available at https://www.sleepfoundation.org/sleep-topics/sleep-hygiene. Last accessed December 3, 2018.

32. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.

33. National Institute of Neurological Disorders and Stroke. Narcolepsy Fact Sheet. Available at https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet. Last accessed December 3, 2018.

34. Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annu Rev Psychol. 2002;53:215-243.

35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

36. Beaudreau SA, Spira AP, Stewart A, et al. Validation of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale in older black and white women. Sleep Med. 2012;13(1):36-42.

37. American Academy of Sleep Medicine. Insomnia: Overview and Facts. Available at http://sleepeducation.org/essentials-in-sleep/insomnia/overview-facts. Last accessed December 3, 2018.

38. American Academy of Sleep Medicine. The Epworth Sleepiness Scale. Available at http://yoursleep.aasmnet.org/pdf/Epworth.pdf. Last accessed December 3, 2018.

39. Sato M, Yamadera W, Matsushima M, Itoh H, Nakayama K. Clinical efficacy of individual cognitive behavior therapy for psychophysiological insomnia in 20 outpatients. Psychiatry Clin Neurosci. 2010;64(2):187-195.

40. Conroy DA, Culebras A. Psychophysiological Insomnia. Available at http://www.medlink.com/article/psychophysiological_insomnia. Last accessed December 3, 2018.

41. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8(8):1-68.

42. National Sleep Foundation. Relaxation Exercise. Available at https://www.sleepfoundation.org/insomnia/content/relaxation-exercise. Last accessed December 3, 2018.

43. Stanford Health Care. Sleep Restriction and CBTI. Available at https://stanfordhealthcare.org/medical-treatments/c/cognitive-behavioral-therapy-insomnia/procedures/sleep-restriction.html. Last accessed December 3, 2018.

44. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007;76(4):517-526.

46. LexiComp Online. Available at http://online.lexi.com. Last accessed December 3, 2018.

47. Harvard Medical School. Overcoming Insomnia. Available at https://www.health.harvard.edu/newsletter_article/overcoming-insomnia. Last accessed December 3, 2018.

48. Shahid A, Chung SA, Phillipson R, Shapiro CM. An approach to long-term sedative-hypnotic use. Nat Sci Sleep. 2012;4:53-61.

49. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365-375.

50. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505-511.

51. Schröder CM, O'Hara R. Depression and obstructive sleep apnea (OSA). Ann Gen Psychiatry. 2005;4:13.

52. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217-1239.

53. Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment.Nutr Clin Pract. 2009;24(6):675-687.

54. Meltzer LJ, Johnson C, Crosette J, Ramos M, Mindell JA. Prevalence of diagnosed sleep disorders in pediatric primary care practices. Pediatrics. 2010;125(6):e1410-e1418.

55. Downey Ralph III. Obstructive Sleep Apnea: Epidemiology. Available at https://emedicine.medscape.com/article/295807-overview#a5. Last accessed December 3, 2018.

56. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-3021.

57. Barvaux VA, Aubert G, Rodenstein DO. Weight loss as a treatment for obstructive sleep apnoea. Sleep Med Rev. 2000;4(5): 435-452.

58. Strobel RJ, Rosen RC. Obesity and weight loss in obstructive sleep apnea: a critical review. Sleep. 1996;19(2):104-115.

59. Vgontzas AN. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch Physiol Biochem. 2008;114(4):211-223.

60. National Institute for Health and Clinical Excellence. Continuous Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome. London: National Institute for Health and Clinical Excellence; 2008.

61. Rajala R, Partinen M, Sane T, Pelkonen R, Huikuri K, Seppäläinen AM. Obstructive sleep apnoea syndrome in morbidly obese patients. J Intern Med. 1991;230(2):125-129.

62. Qaseem A, Holty J-EC, Owens DK, Dallas P, Starkey M, Shekelle P. Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(7):471-483.

63. National Heart, Lung and Blood Institute. CPAP. Available at https://www.nhlbi.nih.gov/health-topics/cpap. Last accessed December 3, 2018.

64. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;307(20):2161-2168.

65. Abuzaid AS, Al Ashry HS, Elbadawi A, et al. Meta-analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea. Am J Cardiol. 2017;120(4):693-699.

66. Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006;(3):CD001106.

67. Aurora RN, Casey KR, Kristo D, et al. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. Sleep. 2010;33(10):1408-1413.

68. American Academy of Sleep Medicine. Narcolepsy: Overview and Facts. Available at http://sleepeducation.org/essentials-in-sleep/narcolepsy. Last accessed December 3, 2018.

69. Sharpless BA, Barber JP. Lifetime prevalence rates of sleep paralysis: a systematic review. Sleep Med Rev. 2011;15(5):311-315.

70. Hishikawa Y. Sleep paralysis. In: Guilleminault C, Dement WC, Passouant P (eds.) Narcolepsy. New York, NY: Spectrum; 1976: 97-124.

71. Ohayon MM, Zulley J, Guilleminault C, Smirne S. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology. 1999;52(6):1194-1200.

72. Cheyne JA. A Webpage About Sleep Paralysis and Associated Hypnagogic and Hypnopompic Experiences. Available at https://sleeptechnologists.org/article/view/389. Last accessed December 3, 2018.

73. Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn. 1999;8(3):319-337.

74. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7(1):93-118.

75. Rubin RL, Hajdukovich RM, Mitler MM. HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. Clin Immunol Immunopathol. 1988;49(1):149-158.

76. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20(11):1012-1020.

77. Oka Y, Inoue Y, Kanbayashi T, et al. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.Sleep. 2006;29(11):1439-1443.

78. Billiard M, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Sonka K. Management of narcolepsy in adults. In: Gilhus NE, Barnes MP, Brainin M (eds). European Handbook of Neurological Management. 2nd ed. Vol. 1. Oxford: Wiley-Blackwell; 2011: 513-528.

79. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-1711.

80. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat. 2008;4(3):557-566.

81. Ferraro L, Antonelli T, Beggiato S, Tomasini MC, Fuxe K, Tanganelli S. The vigilance promoting drug modafinil modulates serotonin transmission in the rat prefrontal cortex and dorsal raphe nucleus: possible relevance for its postulated antidepressant activity. Mini Rev Med Chem. 2013;13(4):478-492.

82. Mamelak M, Swick T, Emsellem H. 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy. Sleep Med. 2015;16:52-58.

83. Xyrem International Study Group Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119-123.

84. Black J, Swick T, Bogan R. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57-62.

85. Black J, Pardi D, Hornfeldt CS. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10:829-835.

86. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939-946.

87. Prinzmetal M, Bloomberg W. The use of benzedrine for treatment of narcolepsy. JAMA. 1935;105:2051-2054.

88. Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol. 2008;578(2-3):209-215.

89. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998;241(2-3):95-98.

90. Narcolepsy Network. Support Groups. Available at http://narcolepsynetwork.org/resources/support-groups. Last accessed December 3, 2018.

91. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2015.

92. MedlinePlus. Idiopathic Hypersomnia. Available at https://www.nlm.nih.gov/medlineplus/ency/article/000803.htm. Last accessed December 3, 2018.

93. Kleine Levin Syndrome Foundation. What is KLS? Available at https://klsfoundation.org/what-is-kleine-levin-syndrome. Last accessed December 3, 2018.

94. Arnulf I, Lin L, Gadoth N, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol. 2008;63(4):482-493.

95. Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L. Restless legs syndrome: prevalence and impact in children and adolescents—the Peds REST study. Pediatrics. 2007;120(2):253-266.

96. MedlinePlus. Sleepwalking. Available at https://www.nlm.nih.gov/medlineplus/ency/article/000808.htm. Last accessed December 3, 2018.

97. Mayo Clinic. Sleepwalking. Available at https://www.mayoclinic.org/diseases-conditions/sleepwalking/symptoms-causes/syc-20353506. Last accessed December 3, 2018.

98. Pressman MR. Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev. 2011;15(5):285-292.

99. National Sleep Foundation. Sleepwalking. Available at https://www.sleepfoundation.org/sleep-disorders-problems/abnormal-sleep-behaviors/sleepwalking. Last accessed December 3, 2018.

100. Mume CO. Prevalence of sleepwalking in an adult population. Libyan J Med. 2010;5:2143.

101. Pressman MR. Factors that predispose, prime and precipitate NREM parasomnias in adults: clinical and forensic implications.Sleep Med Rev. 2007;11(1):5-33.

102. Ohayon MM, Mahowald MW, Dauvilliers Y, Krystal AD, Léger D. Prevalence and comorbidity of nocturnal wandering in the U.S. adult general population. Neurology. 2012;78(20):1583-1589.

103. Sadeh A. Assessment of intervention for infant night waking: parental reports and activity-based home monitoring. J Consult Clin Psychol. 1994;62(1):63-68.

104. Harris M, Grunstein RR. Treatments for somnambulism in adults: assessing the evidence. Sleep Med Rev. 2009;13(4):295-297.

105. Howell MJ. Parasomnias: an updated review. Neurotherapeutics. 2012;9(4):753-775.

106. Guilleminault C, Kirisoglu C, Bao G, Arias V, Chan A, Li KK. Adult chronic sleepwalking and its treatment based on polysomnography. Brain. 2005;128(Pt 5):1062-1069.

107. BMJ Group. Parasomnias in Children. Available at https://bestpractice.bmj.com/topics/en-gb/1177. Last accessed December 3, 2018.

108. Hurwitz TD, Mahowald MW, Schenck CH, Schluter JL, Bundlie SR. A retrospective outcome study and review of hypnosis as treatment of adults with sleepwalking and sleep terror. J Nerv Ment Dis. 1991;179(4):228-233.

109. Hauri PJ, Silber MH, Boeve BF. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J Clin Sleep Med. 2007;3(4):369-373.

110. Frank NC, Spirito A, Stark L, Owens-Stively J. The use of scheduled awakenings to eliminate childhood sleepwalking.J Pediatr Psychol. 1997;22(3):345-353.

111. Remedy's Health Communities. Restless Legs Syndrome/Periodic Limb Movement Disorder Overview. Available athttp://www.healthcommunities.com/rls-plmd/overview-restless-legs-syndrome-periodic-limb-movement-disorder.shtml. Last accessed December 3, 2018.

112. National Institute of Neurological Disorders and Stroke. Restless Legs Syndrome Fact Sheet. Available at https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Restless-Legs-Syndrome-Fact-Sheet. Last accessed December 3, 2018.

113. Rama AN, Kushida CA. Restless legs syndrome and periodic limb movement disorder. Med Clin North Am. 2004;88(3):653-667.

114. Bozorg AM. Restless Legs Syndrome. Available at https://emedicine.medscape.com/article/1188327-overview. Last accessed December 3, 2018.

115. Mitchell UH. Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr Dis Treat. 2011;7:251-257.

116. Allen RP, Earley CJ. Validation of the Johns Hopkins restless legs severity scale. Sleep Med. 2001;2(3):239-242.

117. Atkinson MJ, Allen RP, DuChane J, Murray C, Kushida C, Roth T; RLS Quality of Life Consortium. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res. 2004;13(3):679-693.

118. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385-1396.

119. NPS Radar. Pramipexole (Sifrol) for Severe Primary Restless Legs Syndrome. Available at https://www.nps.org.au/radar/articles/pramipexole-sifrol-for-severe-primary-restless-legs-syndrome. Last accessed December 3, 2018.

120. Bandolier. Gabapentin for RLS. Available at http://www.bandolier.org.uk/booth/RLS/gabap.html. Last accessed December 3, 2018.

121. Hayes WJ, Lemon MD, Farver DK. Gabapentin enacarbil for treatment of restless legs syndrome in adults. Ann Pharmacother. 2012;46(2):229-239.

122. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11(6):512-519.

123. Garcia-Borreguero D, Larrosa O, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897-1904.

124. Mitchell UH, Myrer JW, Johnson AW, Hilton SC. Restless legs syndrome and near-infrared light: an alternative treatment option. Physiother Theory Pract. 2011;27(5):345-351.

125. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131(Pt 4):902-917.

126. Sensory Medical. Relaxis for Medical Professionals. Available at http://myrelaxis.com/relaxis-clinical-data. Last accessed December 3, 2018.

127. Lee KC, Winickoff JP, Kim MK, et al. Resident physicians' use of professional and nonprofessional interpreters: a national survey. JAMA. 2006;296(9):1050-1053.

128. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2):78-85.

129. Lynch EW. Developing cross-cultural competence. In: Lynch EW, Hanson MJ (eds). Developing Cross-Cultural Competence: A Guide for Working With Children and Their Families. 4th ed. Baltimore, MD: Brookes Publishing Company; 2011.

130. Herndon E, Joyce L. Getting the most from language interpreters. Fam Pract Manag. 2004;11(6):37-40.

131. Lee E. Cross-cultural communication: therapeutic use of interpreters. In: Lee E (ed). Working With Asian Americans: A Guide For Clinicians. New York, NY: The Guilford Press; 2000.

132. Raval H, Smith JA. Therapists' experiences of working with language interpreters. Int J Ment Health. 2003;32(2):6-31.

Evidence-Based Practice Recommendations Citations

1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. Available at https://aasm.org/resources/clinicalguidelines/040515.pdf. Last accessed December 7, 2018.

2. Qaseem A, Dallas P, Owens DK, Starkey M, Holty JE, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(3):210-220. Available at http://annals.org/aim/fullarticle/1892620. Last accessed December 7, 2018.

3. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;11(7):773-827. Available at http://jcsm.aasm.org/ViewAbstract.aspx?pid=30098. Last accessed December 7, 2018.

4. Billiard M, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Sonka K. Management of narcolepsy in adults. In: Gilhus NE, Barnes MP, Brainin M (eds). European Handbook of Neurological Management. 2nd ed. Vol 1. Oxford: Wiley-Blackwell; 2011. Available at https://www.eaneurology.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2011_Management_of_narcolepsy_in_adults.pdf. Last accessed December 7, 2018.

5. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. Sleep. 2012;35(8):1039-1062. Available at https://aasm.org/resources/practiceparameters/updateto.pdf. Last accessed December 7, 2018.



Privacy Policy
Copyright © 2019 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.